Urticaria and Angioedema in Renal Cell Cancer Patients Treated with IL-2

REFERENCES

• Rosenberg S. A., Yang J. C., Topalian S. L., Schwartzentruber D. J., Weber J. S., et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 1994; 271(12)907–913
   PubMed Web of Science ®Google Scholar
• Rosenberg S. A., Lotze M. T., Yang J. C., Aebersold P. M., Linehan W. M., et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann. Surg. 1989; 210(4)474–484
   PubMed Web of Science ®Google Scholar
• Wolkenstein P., Chosidow O., Wechsler J., Guillaume J. C., Lescs M. C., et al. Cutaneous side effects associated with interleukin 2 administration for metastatic melanoma. J. Am. Acad. Dermatol. 1993; 28(1)66–70
   PubMed Web of Science ®Google Scholar
• Heywood G. R., Rosenberg S. A., Weber J. S. Hypersensitivity reactions to chemotherapy agents in patients receiving chemoimmunotherapy with high-dose interleukin 2. J. Natl. Cancer Inst. 1995; 87(12)915–922
   PubMed Web of Science ®Google Scholar
• Gaspari A. A., Lotze M. T., Rosenberg S. A., Stern J. B., Katz S. I. Dermatologic changes associated with interleukin 2 administration. JAMA 1987; 258(12)1624–1629
   PubMed Web of Science ®Google Scholar
• Baars J. W., Wagstaff J., Hack C. E., Wolbink G. J., Eerenberg-Belmer A. J., Pinedo H. M. Angioneurotic oedema and urticaria during therapy with interleukin-2 (IL-2). Ann. Oncol. 1992; 3(3)243–244
   PubMed Web of Science ®Google Scholar
• Yang J. C., Topalian S. L., Parkinson D., Schwartzentruber D. J., Weber J. S., et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J. Clin. Oncol. 1994; 12(8)1572–1576
   PubMed Web of Science ®Google Scholar
• Yang J. C., Sherry R. M., Steinberg S. M., Topalian S. L., Schwartzentruber D. J., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J. Clin. Oncol. 2003; 21(16)3127–3132
   PubMed Web of Science ®Google Scholar
• Bock S. N., Lee R. E., Fisher B., Rubin J. T., Schwartzentruber D. J., et al. A prospective randomized trial evaluating prophylactic antibiotics to prevent triple-lumen catheter-related sepsis in patients treated with immunotherapy. J. Clin. Oncol. 1990; 8(1)161–169
   PubMed Web of Science ®Google Scholar
• Hartmann L. C., Urba W. J., Steis R. G., Smith J. W., Vander Molen L. A., et al. Use of prophylactic antibiotics for prevention of intravascular catheter-related infections in interleukin-2-treated patients. J. Natl. Cancer. Inst. 1989; 81(15)1190–1193
   PubMed Web of Science ®Google Scholar
• Aldesleukin. American Hospital Formulary Service Drug Information. American Society of Health System Pharmacists, Inc., Bethesda, MD 1999; 786–791
   Google Scholar
• Thijs L. G., Hack C. E., Strack van Schijndel R. J., Nuijens J. H., Wolbink G. J., et al. Activation of the complement system during immunotherapy with recombinant IL-2, relation to the development of side effects. J. Immunol. 1990; 144(6)2419–2424
   PubMed Web of Science ®Google Scholar
• Levi-Schaffer F., Segal V., Shalit M. Effects of interleukins on connective tissue type mast cells co-cultured with fibroblasts. Immunology 1991; 72(2)174–180
   PubMed Web of Science ®Google Scholar
• Rubinchik E., Norris A., Levi-Schaffer F. Modulations of histamine release from mast cells by interleukin-2 is affected by nedocromil sodium. Int. J. Immunopharmacol. 1995; 17(7)563–570
   PubMed Web of Science ®Google Scholar
• Silberstein D. S., Schoof D. D., Rodrick M. L., Tai P. C., Spry C. J., et al. Activation of eosinophils in cancer patients treated with IL-2 and IL-2-generated lymphokine-activated killer cells. J. Immunol. 1989; 142(6)2162–2167
   PubMed Web of Science ®Google Scholar
• Ettinghausen S. E., Moore J. G., White D. E., Platanias L., Young N. S., Rosenberg S. A. Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood 1987; 69(6)1654–1660
   PubMed Web of Science ®Google Scholar
• Rivoltini L., Viggiano V., Spinazze S., Santoro A., Colombo M. P., et al. In vitro anti-tumor activity of eosinophils from cancer patients treated with subcutaneous administration of interleukin 2, role of interleukin 5. Int. J. Cancer 1993; 54(1)8–15
   PubMed Web of Science ®Google Scholar
• van Haelst P. C., Kovach J. S., Kita H., Leiferman K. M., Gleich G. J., et al. Administration of interleukin-2 (IL-2) results in increased plasma concentrations of IL-5 and eosinophilia in patients with cancer. Blood 1991; 78(6)1538–1544
   PubMed Web of Science ®Google Scholar
• Rand T. H., Silberstein D. S., Kornfeld H., Weller P. F. Human eosinophils express functional interleukin 2 receptors. J. Clin. Invest. 1991; 88(3)825–832
   PubMed Web of Science ®Google Scholar
• Levi-Schaffer F., Barkans J., Newman T. M., Ying S., Wakelin M., et al. Identification of interleukin-2 in human peripheral blood eosinophils. Immunology 1996; 87(1)155–161
   PubMed Web of Science ®Google Scholar
• Hoenstein R., Admon D., Solomon A., Norris A., Moqbel R. Levi-Schaffer, F. Interleukin-2 activates human peripheral blood eosinophils. Cell Immunol. 2001; 210(2)116–124
   PubMed Web of Science ®Google Scholar
• Simon H. U., Plotz S., Simon D., Seitzer U., Braathen L. R., et al. Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome. Eur. J. Immunol. 2003; 33(4)834–89
   PubMed Web of Science ®Google Scholar
• Piliponsky A. M., Gleich G. J., Bar I., Levi-Schaffer F. Effects of eosinophils on mast cells: a new pathway for the perpetuation of allergic inflammation. Mol. Immunol. 2002; 38(16–18)1369–1372
   PubMed Web of Science ®Google Scholar
• Piliponsky A. M., Gleich G. J., Nagler A., Bar I., Levi-Schaffer F. Non-IgE-dependent activation of human lung- and cord blood-derived mast cells is induced by eosinophil major basic protein and modulated by the membrane form of stem cell factor. Blood 2003; 101(5)1898–1904
   PubMed Web of Science ®Google Scholar
• Munitz A., Levi-Schaffer F. Eosinophils: ‘new’ roles for ‘old’ cells. Allergy 2004; 59(3)268–275
   PubMed Web of Science ®Google Scholar